Fertilization in Vitro — Cardiac Output Monitoring in IVF Patients
Citation(s)
Armstrong S, Fernando R, Columb M Minimally- and non-invasive assessment of maternal cardiac output: go with the flow! Int J Obstet Anesth. 2011 Oct;20(4):330-40. doi: 10.1016/j.ijoa.2011.07.006. Epub 2011 Sep 16. Review.
Chan WS, Dixon ME The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121(6):713-26. Epub 2007 Jul 30. Review.
Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC In vitro fertilization-induced alterations in coagulation and fibrinolysis as measured by thromboelastography. Anesth Analg. 2002 Oct;95(4):1063-6, table of contents.
Liang PY, Yin B, Cai J, Hu XD, Song C, Wu TH, Zhao J, Li GG, Zeng Y Increased circulating Th1/Th2 ratios but not other lymphocyte subsets during controlled ovarian stimulation are linked to subsequent implantation failure after transfer of in vitro fertilized embryos. Am J Reprod Immunol. 2015 Jan;73(1):12-21. doi: 10.1111/aji.12320. Epub 2014 Sep 15.
Magnani B, Tsen L, Datta S, Bader A In vitro fertilization. Do short-term changes in estrogen levels produce increased fibrinolysis? Am J Clin Pathol. 1999 Oct;112(4):485-91.
Salmassi A, Mettler L, Jonat W, Buck S, Koch K, Schmutzler AG Circulating level of macrophage colony-stimulating factor can be predictive for human in vitro fertilization outcome. Fertil Steril. 2010 Jan;93(1):116-23. doi: 10.1016/j.fertnstert.2008.09.083. Epub 2008 Nov 8.
Wu MY, Chen HF, Chen SU, Chao KH, Yang YS, Ho HN Increase in the production of interleukin-10 early after implantation is related to the success of pregnancy. Am J Reprod Immunol. 2001 Dec;46(6):386-92.
Cardiac Output Monitoring in Patients Undergoing In Vitro Fertilization by Noninvasive Cardiac Impendence: A Prospective Observational Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.